Association of hereditary angioedema and hereditary breast cancer

Cancer Genetics and Cytogenetics

Volumn 95, Issue 2, 1997, Pages 159-162

  Christie, David R H ^a   Kirk, Judy A ^a   Clarke, Christine L ^a   Boyages, John ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; PRIORITY JOURNAL;

AGED; ANGIONEUROTIC EDEMA; BREAST NEOPLASMS; DANAZOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PEDIGREE;

EID: 0030927879     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00218-X     Document Type: Article

References (23)

1. Carreer FMJ (1992): The C1 inhibitor deficiency: A review. Eur J Chem Clin Biochem 30:793-807.
2. Davis AE (1988): C1 Inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 6:595-628.
3. Frank MM, Gelfand JA, Atkinson JP (1976): Hereditary angioedema; the clinical syndrome and its management. Ann Int Med 84:580-593.
4. Gelfand JA, Boss CR, Conley CL, Reinhart R, Frank MM (1979): Acquired C1 esterase inhibitor deficiency and angioedema: A review. Medicine 58:311-318.
5. Bain BJ, Catavsky D, Ewan P (1993): Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B-lymphocytes. Cancer 73:3318-3322.
6. Agostini A, Cicardi M (1992): Hereditary and acquired C1-inhibitor: Biological and clinical characteristics. Medicine 71:4:206-215.
7. Cicardi M, Bisiani G, Cugno M, Spath P, Agostini A (1993): Autoimmune C1 inhibitor deficiency: Report of eight patients. Am J Med 95:169-175.
8. Ponder B (1994): Searches begin and end. Nature 371:279.
9. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochrane C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rostek P, Lai M, Barren JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wise-man R, Kamb A, Skolnick MH (1994): A strong candidate for the 17q linked breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
10. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir G, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormison W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR (1994): Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090.
11. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Birnbaum D, Gaudray P, Theillet C (1994): Patterns of amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosom Cancer 9:42-48.
12. Ung O, Langlands AO, Barraclough B, Boyages J (1995): Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol 13:435-443.
13. Barbieri RL (1990): Danazol: Molecular, endocrine and clinical pharmacology. Prog Clin Biol Res 323:241-252.
14. Peters TG, Lewis JD, Wilkinson EJ, Fuhrman TM (1977): Danazol therapy in hormone-sensitve mammary carcinoma. Cancer 40:2797-2800.
15. Escrich E, Ribalta T, Muntane J, de Villa MCR, Murillo J, Saez S (1991): Effects of an androgen derivative on pre-established mammary tumours chemically induced in the rat. J Cancer Res Clin Oncol 117:575-582.
16. Escrich E, Solanas M, Bailly GH, de Villa MCR, Saez S (1994): Effects of androgenic derivative on the development of chemically-induced mammary carcinogenesis in the rat. Anticancer Res 14:539-544.
17. Bishop JF, Smith JG, Jeal PN, Murray R, Drummond RM, Pitt P, Olver IN, Bhowal AK (1993): The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: A randomised doubleblind placebo controlled trial. Eur J Cancer 29:6:814-818.
18. Coombes RC, Dearnley D, Humphreys J, Gazet JC, Ford HT, Nash AG, Mashiter K, Powles TJ (1980): Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073-1076.
19. Powles TJ, Gordon C, Coombes RC (1982): Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethamide-danazol compared to tamoxifen used alone. Cancer Res 42:3458s-3460s.
20. Vliagoftis H, Dimitriadou V, Boucher W, Rozniecki JJ, Correira I, Raam S, Theoharides TC (1992): Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 98:4:398-409.
21. Ross JG, Hussey DH, Mayr NA, Davis CS (1993): Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 71:3744-3752.
22. Bentzen SM, Overgaard J (1994): Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Sem Radiat Oncol 4:4:68-80.
23. Sheffer A, Aysten KF, Rosen FS, Fearon DT (1985): Acquired deficiency of the inhibitor of the first component of complement: Report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol 75:640-646.